Weight-Loss drug tested for common hormone disorder
NCT ID NCT06222437
Summary
This early-stage study aimed to see if the medication semaglutide, often used for diabetes and weight loss, could help manage symptoms of Polycystic Ovary Syndrome (PCOS). It planned to look at effects on menstrual cycles, hormone levels, weight, and blood sugar in women with PCOS and a higher body mass index. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Institute at Methodist Health System
Dallas, Texas, 75203, United States
Conditions
Explore the condition pages connected to this study.